Clinical comparison of selective and non-selective alpha(1A)- adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: Studies on tamsulosin and terazosin in Chinese patients

Journal of Medicine

Volumn 29, Issue 5-6, 1998, Pages 289-303

  Na, Yan Jung ^a   Guo, Y L ^a   Gu, Fang Liu ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

1 Adrenoceptor antagonists; Benign prostatic hyperplasia; Bladder outlet; Bladder obstruction; Tamsulosin; Terazosin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN; TERAZOSIN;

ARTICLE; BLADDER NECK STENOSIS; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; PRAZOSIN; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; SINGLE-BLIND METHOD; SULFONAMIDES; TREATMENT OUTCOME; URINARY BLADDER NECK OBSTRUCTION;

EID: 0032317432     PISSN: 00257850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Abrams, P., Schulman, C.C., Vaage, S. and the European Tamsulosin Study Group. (1955). Tamsulosin, a selective alpha(1c)-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br. J. Urol. 76: 325-336.
2. 1-adrenoceptors and uroselectivity. Prostate 30: 202-215.
3. 1-adrenoceptor subtypes in the human prostate. Br. J. Urol. 74: 585-589.
4. 1-adrenergic selectivity? Br. J. Urol. 76 Suppl 1: 47-55.
5. 1-adrenoceptor antagonists in benign prostatic hyperplasia (BPH): rationale and clinical experience. Eur. Urol. 29: 129-144.
6. Chapple, C.R., Baert, L., Thirnd, P., Hofner, K., Khoe, G.S.S., Spangberg, A. (1997). Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of prostatic obstruction. European Urol. 32: 462-470.
7. 1-receptors in the control of peripheral resistance. Am. Heart J. 116: 133-162.
8. 1-adrenoceptor subtypes present in the human prostate. Life Sci. 54: 1595-1605.
9. 1-adrenoceptos to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur. J. Mol. Pharmacol. 288: 201-207.
10. 1-adrenoceptor classification: sharpening Occam's razor. Trends Pharmacol. Sci. 15: 167-170.
11. 1C subtype. Mol. Pharmacol. 45: 703-708.
12. 1-adrenoceptor subtype selectivity of tamsulosin: studies using livers from different species. Eur. J. Mol. Pharmacol. 15: 289:1-7.
13. Gormley, G., Stoner, E., Bruskewitz, R.C., Imperato-Mcgrnley, J., Walsch, P.C., McConnell, J.D., Andriole, G.L., Geller, J., Brachen, B.R., Tenover, J.S., Vaughan, D., Pappas, F., Taylor, A., Binkowiz, B. and Milroy, E.J.G. (1992). The effects of finasteride in men with benign prostatic hyperplasia. N. Eng. J. Med. 327: 1185-1191.
14. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Brit. J. Pharmacol. 113: 723-728.
15. Holtgrewe, H.L. (1998). Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology 51 Suppl 4A: 1-7.
16. Homma, Y., Imajo, C. and Kawabe, K. (1995). Response criteria of treatments for benign prostatic hyperplasia. Int. J. Urol. 2: 33-38.
17. Jardin, A., Bensadoun, H., Delauche-Cavallier, M.C., Attali, P. and BPH-ALF Group. (1991). Alfuzosin for treatment of benign prostatic hypertrophy. Lancet. 337: 1457-1461.
18. Jonler, M., Riehmann, M. and Bruskewitz, R.C. (1994). Benign prostatic hyperplasia. Current pharmacological treatment. Drugs. 471: 66-81.
19. 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J. Urol. 144: 908-911.
20. Kawabe, K. (1995). Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Brit. J. Urol. 76 Suppl. 1: 63-67.
21. Kirby, R.S., Coppinger, S.W.C., Corcoran, M.O., Chapple, C.R. and Flannigan, (1987). Prazosin in the treatment of prostatic obstruction: a placebo-control study. 2 Br. J. Urol. 60: 136-142.
22. Lepor, H., Auerbach, S., Puras-Baez, A., Narayan, P., Soloway, M., Lowe, F., Moon, T., Leifer, G. and Madsen, P. (1992). A randomized, placebo-controlled multi-center study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol. 148: 1467-1474.
23. Lepor, H., Tang, R. and Meretyk, S. (1993a). Alpha adrenoceptor subtypes in the human prostate. J. Urol. 149: 640-642.
24. Lepor, H., Tang, R. and Shapiro, E. (1993b). The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate. 22: 301-307.
25. 1C antagonist [abstract] J. Urol. 153 Suppl. 274.
26. Lepor, H. for the Tamsulosin Investigator Group. (1998a). Phase III multi-center placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 51: 892-900.
27. Lepor, H. for the Tamsulosin Investigator Group. (1998b). Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial. Urology 51: 901-906.
28. 1-adrenoceptor subtypes. Naunyn. Schmiedebergs. Arch. Pharmacol. 350: 136-142.
29. 1-adrenoceptors in human prostates with benign prostatic hypertrophy. Urol. Res. 22: 273-278.
30. 1A-adrenergic receptors in the isolated human prostate. Pharmacol. Commun. 4(39): 181-188.
31. 1D-adrenoceptor subtypes. Brit. J. Pharmacol. 120: 231-238.
32. Price, D.T., Schwinn, D.A., Lomasney, J.W., Allen, L.F., Caron, M.G. and Lefkowitz, R.J. (1993). Identification, quantification, and localization of mRNA for three distinct alpha adrenergic receptor subtypes in human prostate. J. Urol. 150: 546-551.
33. 1A/D subtypes. [abstract no. 678]. Proceedings of the 23rd Congress of the International Society of Urology. Sep 18-22; Sydney.
34. Tsunoo, M., Shishito, A., Soeishi, Y., Kobori, M. and Shimoyama, M. (1990). Phase I clinical trial of YM617, a new alpha 1 adrenoceptor antagonist-first report: a single oral dose of conventional formulation in healthy male subjects [in Japanese]. Rinsho Iyaku. 6(12): 2503-2528.
35. Yamada, S., Suzuki, M, Kato, Y., Kimura, R., Mori, R., Matsumoto, K., Maruyama, M. and Kawabe, K. (1992). Binding characteristics of naftopidil and adrenoceptors in benign prostatic hypertrophy. Life Sci. 50(2): 127-135.
36. 1 antagonists. Life Sci. 54: 1845-1854.
37. 1-adrenoceptors in human prostates with benign prostatic hypertrophy. Urol. Res. 22: 272-278.
38. 1-adrenoceptor antagonist binding in human prostate and aorta. Clin. Exp. Pharmacol. Physiol. 21: 405-411.